Supernus Pharmaceuticals (SUPN) Total Debt Growth (1y) (2012 - 2025)
Supernus Pharmaceuticals (SUPN) Total Debt Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 41.53% |
| 10 | Supernus Pharmaceuticals | 2.67 Bn | 2.30 Bn | 185.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.41% |
| Sep 30, 2025 | -75.88% |
| Mar 31, 2025 | -41.61% |
| Dec 31, 2024 | -9.08% |
| Sep 30, 2024 | 1.53% |
| Jun 30, 2024 | 128.30% |
| Mar 31, 2024 | -34.43% |
| Dec 31, 2023 | 146.54% |
| Sep 30, 2023 | -3.59% |
| Jun 30, 2023 | -56.14% |
| Mar 31, 2023 | 67.12% |
| Dec 31, 2022 | -95.02% |
| Sep 30, 2022 | 101.91% |
| Jun 30, 2022 | 100.68% |
| Mar 31, 2022 | 48.76% |
| Dec 31, 2021 | 1,272.47% |
| Sep 30, 2021 | -71.57% |
| Mar 31, 2013 | -30.88% |
| Dec 31, 2012 | -22.35% |